Xiao-Jie Lu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Xiao-Jie Lu has a total of 131 co-authors. Here are the top co-authors by number of shared publications:
- Jin-Yu Sun
Department of Cardiology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China
9 shared publications - Jincheng Wang
Laboratory for Biomarker Imaging Science, Graduate School of Biomedical Science and Engineering Hokkaido University Sapporo Japan
8 shared publications - Beicheng Sun
Department of Hepatobiliary Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230001, China; Innovative Institute of Tumor Immunity and Medicine (ITIM), Hefei, Anhui, China; Anhui Province Key Laboratory of Tumor Immune Microenvironment and Immunotherapy, Hefei, Anhui, China; Anhui Provincial Innovation Institute for Pharmaceutical Basic Research, Hefei, Anhui, 230001, China
4 shared publications - Jiansong Ji
Department of Radiology, Lishui Hospital of Zhejiang University, Lishui, China
4 shared publications - Xiaochen Wang
Nanjing Medical University
4 shared publications Huabing Tan
Department of Infectious Diseases, Hepatology Institute, Renmin Hospital, Hubei University of Medicine, Shiyan, Hubei 442000, China; Virology Key Laboratory of Shiyan City, Hubei University of Medicine, Shiyan 442000, Hubei Province, China
3 shared publications
Latest Publications
- Open Access
- 16 May 2026
- Published by Elsevier in Molecular Therapy Oncology
- Vol. 34 (2)
Multi-omics dissection of R-loop dynamics in tumorigenesis: From transcription-replication conflict to therapeutic targets
- 16 May 2026
- Published by Elsevier in Molecular Therapy Oncology
- Vol. 34 (2)
Open AccessMulti-omics dissection of R-loop dynamics in tumorigenesis: From transcription-replication conflict to therapeutic targets
- Open Access
- 17 October 2024
- Published by Wolters Kluwer Health in Clinical and Translational Gastroenterology
- Vol. 15 (12) , e00780
A Multi-Institutional Study on Ultrasound Image Analysis for Staging HBV-Derived Liver Fibrosis: A Potential Noninvasive Alternative to Liver Stiffness Measurement
INTRODUCTION: Liver stiffness measurement is principal for staging liver fibrosis but not included in routine examinations. We investigated whether comparable diagnostic performance can be achieved by mining ultrasound images and developing a novel serum index (NSI). METHODS: Texture features were extracted from ultrasound images. Spearman correlation and logistics regression selected independent variables for significant (F ≥ 2) and advanced (F ≥ 3) fibrosis. We compared the diagnostic performance of transient elastography (TE), ultrasound image biomarker, conventional serum indices (aspartate aminotransferase-to-platelet ratio index, fibrosis-4 index, gamma-glutamyl transpeptidase-to-platelet ratio), and NSI in 365 patients with chronic hepatitis B. RESULTS: Among patients, 52.1% had significant fibrosis and 24.2% had advanced fibrosis. PLT, gamma-glutamyl transferase, prealbumin, and globulin were incorporated into NSI. In the validation group, TE achieved the best performance (area under the curve [AUC]: 0.765 [0.690–0.849] for significant fibrosis; 0.812 [0.745–0.878] for advanced fibrosis), followed by ultrasound image biomarker (AUC: 0.712 [0.629–0.795]; 0.678 [0.595–0.763]) and NSI (AUC: 0.630 [0.534–0.725]; 0.659 [0.572–0.745]), outperforming conventional indices. DISCUSSION: Texture analysis enhances ultrasound's diagnostic utility, but TE remains superior. When TE is unavailable, ultrasound image analysis and NSI, incorporating prealbumin, can serve as alternative tools for fibrosis staging.
- 17 October 2024
- Published by Wolters Kluwer Health in Clinical and Translational Gastroenterology
- Vol. 15 (12) , e00780
Open AccessA Multi-Institutional Study on Ultrasound Image Analysis for Staging HBV-Derived Liver Fibrosis: A Potential Noninvasive Alternative to Liver Stiffness Measurement
INTRODUCTION: Liver stiffness measurement is principal for staging liver fibrosis but not included in routine examinations. We investigated whether comparable diagnostic performance can be achieved by mining ultrasound images and developing a novel serum index (NSI). METHODS: Texture features were extracted from ultrasound images. Spearman correlation and logistics regression selected independent variables for significant (F ≥ 2) and advanced (F ≥ 3) fibrosis. We compared the diagnostic performance of transient elastography (TE), ultrasound image biomarker, conventional serum indices (aspartate aminotransferase-to-platelet ratio index, fibrosis-4 index, gamma-glutamyl transpeptidase-to-platelet ratio), and NSI in 365 patients with chronic hepatitis B. RESULTS: Among patients, 52.1% had significant fibrosis and 24.2% had advanced fibrosis. PLT, gamma-glutamyl transferase, prealbumin, and globulin were incorporated into NSI. In the validation group, TE achieved the best performance (area under the curve [AUC]: 0.765 [0.690–0.849] for significant fibrosis; 0.812 [0.745–0.878] for advanced fibrosis), followed by ultrasound image biomarker (AUC: 0.712 [0.629–0.795]; 0.678 [0.595–0.763]) and NSI (AUC: 0.630 [0.534–0.725]; 0.659 [0.572–0.745]), outperforming conventional indices. DISCUSSION: Texture analysis enhances ultrasound's diagnostic utility, but TE remains superior. When TE is unavailable, ultrasound image analysis and NSI, incorporating prealbumin, can serve as alternative tools for fibrosis staging.
- Open Access
- 29 March 2024
- Published by Elsevier in Pharmacological Research
- Vol. 203, 107161
Molecular insight into T cell exhaustion in hepatocellular carcinoma
- 29 March 2024
- Published by Elsevier in Pharmacological Research
- Vol. 203, 107161
Open AccessMolecular insight into T cell exhaustion in hepatocellular carcinoma
- 23 August 2023
- Published by Elsevier in Cancer Letters
- Vol. 573, 216354
The tumour-promoting role of protein homeostasis: Implications for cancer immunotherapy
- 23 August 2023
- Published by Elsevier in Cancer Letters
- Vol. 573, 216354
The tumour-promoting role of protein homeostasis: Implications for cancer immunotherapy
- Open Access
- 20 August 2023
- Published by Elsevier in Cytokine & Growth Factor Reviews
- Vol. 75, 101-109
Ferroptosis in cancer immunity and immunotherapy: Multifaceted interplay and clinical implications
- 20 August 2023
- Published by Elsevier in Cytokine & Growth Factor Reviews
- Vol. 75, 101-109
Open AccessFerroptosis in cancer immunity and immunotherapy: Multifaceted interplay and clinical implications
- Top Cited Papers
- 22 March 2023
- Published by Elsevier in Pharmacology & Therapeutics
- Vol. 245, 108391
PPAR-γ signaling in nonalcoholic fatty liver disease: Pathogenesis and therapeutic targets
- 22 March 2023
- Published by Elsevier in Pharmacology & Therapeutics
- Vol. 245, 108391
Top Cited PapersPPAR-γ signaling in nonalcoholic fatty liver disease: Pathogenesis and therapeutic targets
- Open Access
- 25 December 2022
- Published by International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA) in BioScience Trends
- Vol. 16 (6) , 405-425
An overview: Management of patients with advanced hepatocellular carcinoma
Hepatocellular carcinoma (HCC) has constituted a significant health burden worldwide, and patients with advanced HCC, which is stage C as defined by the Barcelona Clinic Liver Cancer staging system, have a poor overall survival of 6-8 months. Studies have indicated the significant survival benefit of treatment based on sorafenib, lenvatinib, or atezolizumab-bevacizumab with reliable safety. In addition, the combination of two or more molecularly targeted therapies (first- plus second-line) has become a hot topic recently and is now being extensively investigated in patients with advanced HCC. In addition, a few biomarkers have been investigated and found to predict drug susceptibility and prognosis, which provides an opportunity to evaluate the clinical benefits of current therapies. In addition, many therapies other than tyrosine kinase inhibitors that might have additional survival benefits when combined with other therapeutic modalities, including immunotherapy, transarterial chemoembolization, radiofrequency ablation, hepatectomy, and chemotherapy, have also been examined. This review provides an overview on the current understanding of disease management and summarizes current challenges with and future perspectives on advanced HCC.
- 25 December 2022
- Published by International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA) in BioScience Trends
- Vol. 16 (6) , 405-425
Open AccessAn overview: Management of patients with advanced hepatocellular carcinoma
Hepatocellular carcinoma (HCC) has constituted a significant health burden worldwide, and patients with advanced HCC, which is stage C as defined by the Barcelona Clinic Liver Cancer staging system, have a poor overall survival of 6-8 months. Studies have indicated the significant survival benefit of treatment based on sorafenib, lenvatinib, or atezolizumab-bevacizumab with reliable safety. In addition, the combination of two or more molecularly targeted therapies (first- plus second-line) has become a hot topic recently and is now being extensively investigated in patients with advanced HCC. In addition, a few biomarkers have been investigated and found to predict drug susceptibility and prognosis, which provides an opportunity to evaluate the clinical benefits of current therapies. In addition, many therapies other than tyrosine kinase inhibitors that might have additional survival benefits when combined with other therapeutic modalities, including immunotherapy, transarterial chemoembolization, radiofrequency ablation, hepatectomy, and chemotherapy, have also been examined. This review provides an overview on the current understanding of disease management and summarizes current challenges with and future perspectives on advanced HCC.
- Open Access
- 14 December 2022
- Published by Frontiers Media SA in Frontiers in Physiology
- Vol. 13, 1046497
Non-invasive methods to evaluate liver fibrosis in patients with non-alcoholic fatty liver disease
Non-alcoholic Fatty Liver Disease (NAFLD) is a chronic liver disease that is strongly related to insulin resistance and metabolic syndrome, and it has become the most common liver disorder in developed countries. NAFLD embraces the full pathological process of three conditions: steatosis, non-alcoholic steatohepatitis, and finally, cirrhosis. As NAFLD progresses, symptoms will become increasingly severe as fibrosis develops. Therefore, evaluating the fibrosis stage is crucial for patients with NAFLD. A liver biopsy is currently considered the gold standard for staging fibrosis. However, due to the limitations of liver biopsy, non-invasive alternatives were extensively studied and validated in patients with NAFLD. The advantages of non-invasive methods include their high safety and convenience compared with other invasive approaches. This review introduces the non-invasive methods, summarizes their benefits and limitations, and assesses their diagnostic performance for NAFLD-induced fibrosis.
- 14 December 2022
- Published by Frontiers Media SA in Frontiers in Physiology
- Vol. 13, 1046497
Open AccessNon-invasive methods to evaluate liver fibrosis in patients with non-alcoholic fatty liver disease
Non-alcoholic Fatty Liver Disease (NAFLD) is a chronic liver disease that is strongly related to insulin resistance and metabolic syndrome, and it has become the most common liver disorder in developed countries. NAFLD embraces the full pathological process of three conditions: steatosis, non-alcoholic steatohepatitis, and finally, cirrhosis. As NAFLD progresses, symptoms will become increasingly severe as fibrosis develops. Therefore, evaluating the fibrosis stage is crucial for patients with NAFLD. A liver biopsy is currently considered the gold standard for staging fibrosis. However, due to the limitations of liver biopsy, non-invasive alternatives were extensively studied and validated in patients with NAFLD. The advantages of non-invasive methods include their high safety and convenience compared with other invasive approaches. This review introduces the non-invasive methods, summarizes their benefits and limitations, and assesses their diagnostic performance for NAFLD-induced fibrosis.
- 1 October 2021
- Published by Elsevier in Cellular Signalling
- Vol. 86, 110100
Circular RNA and human diseases: Basic research and translational implications
- 1 October 2021
- Published by Elsevier in Cellular Signalling
- Vol. 86, 110100
Circular RNA and human diseases: Basic research and translational implications
- Open Access
- 3 August 2021
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 12, 705950
Placental Immune Tolerance and Organ Transplantation: Underlying Interconnections and Clinical Implications
The immune system recognizes and attacks non-self antigens, making up the cornerstone of immunity activity against infection. However, during organ transplantation, the immune system also attacks transplanted organs and leads to immune rejection and transplantation failure. Interestingly, although the embryo and placenta are semi-allografts, like transplanted organs, they can induce maternal tolerance and be free of a vigorous immune response. Also, embryo or placenta-related antibodies might adversely affect subsequent organ transplantation despite the immune tolerance during pregnancy. Therefore, the balance between the immune tolerance in maternal-fetal interface and normal infection defense provides a possible desensitization and tolerance strategy to improve transplantation outcomes. A few studies on mechanisms and clinical applications have been performed to explore the relationship between maternal-fetal immune tolerance and organ transplantation. However, up to now, the mechanisms underlying maternal-fetal immune tolerance remain vague. In this review, we provide an overview on the current understanding of immune tolerance mechanisms underlying the maternal-fetal interface, summarize the interconnection between immune tolerance and organ transplantation, and describe the adverse effect of pregnancy alloimmunization on organ transplantation.
- 3 August 2021
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 12, 705950
Open AccessPlacental Immune Tolerance and Organ Transplantation: Underlying Interconnections and Clinical Implications
The immune system recognizes and attacks non-self antigens, making up the cornerstone of immunity activity against infection. However, during organ transplantation, the immune system also attacks transplanted organs and leads to immune rejection and transplantation failure. Interestingly, although the embryo and placenta are semi-allografts, like transplanted organs, they can induce maternal tolerance and be free of a vigorous immune response. Also, embryo or placenta-related antibodies might adversely affect subsequent organ transplantation despite the immune tolerance during pregnancy. Therefore, the balance between the immune tolerance in maternal-fetal interface and normal infection defense provides a possible desensitization and tolerance strategy to improve transplantation outcomes. A few studies on mechanisms and clinical applications have been performed to explore the relationship between maternal-fetal immune tolerance and organ transplantation. However, up to now, the mechanisms underlying maternal-fetal immune tolerance remain vague. In this review, we provide an overview on the current understanding of immune tolerance mechanisms underlying the maternal-fetal interface, summarize the interconnection between immune tolerance and organ transplantation, and describe the adverse effect of pregnancy alloimmunization on organ transplantation.